Try our Advanced Search for more refined results
Life Sciences
-
November 26, 2025
Health Plans Defend Renewed Biogen MS Drug Scheme Suit
Health plans claiming Biogen Inc. illegally stifled competition for its multiple sclerosis drug Tecfidera have said an Illinois federal judge should let their latest complaint proceed to discovery because it fixes earlier pleading deficiencies and better outlines the drugmaker's allegedly anticompetitive scheme.
-
November 26, 2025
Calif. Cannabis Workers Settle Suit Over Quotas, Lack Of Pay
Hourly agricultural laborers who accused California cannabis company Glass House Brands Inc. and some of its subsidiaries of bilking them out of sick pay, minimum wage and lunch breaks while enforcing quotas have agreed to settle what is left of their state court labor violation lawsuit for $305,000.
-
November 26, 2025
Paratek Beats Suit Alleging $462M Sale Built On D&O Interests
A Delaware vice chancellor tossed investor challenges to Paratek Pharmaceuticals' $462 million sale to Gurnet Point Capital and Novo Holdings, saying it was not reasonably conceivable that directors and officers undermined better deal prospects in order to protect personal interests.
-
November 26, 2025
GTCR Drops FTC Constitutional Challenge Over Merger Case
GTCR BC Holdings LLC has agreed to dismiss its constitutional claims against the Federal Trade Commission after enforcers dropped their case challenging the private equity firm's $627 million purchase of medical device coatings company Surmodics Inc.
-
November 26, 2025
Avantor Sued Over Supply Chain Issues After $6.4B Deal
Investors have accused executives at Pennsylvania-based laboratory supplier Avantor Inc. of falsely inflating the company's stock value by continually touting the value of its $6.4 billion merger with a major distributor in 2017, even as its failures to maintain its supply chain mounted, according to a proposed class action filed Tuesday in federal court.
-
November 26, 2025
MVP: Ropes & Gray's Abigail Gregor
Abigail Gregor of Ropes & Gray LLP advised Bain Capital on the formation of a new biopharmaceutical company focused on autoimmune disease treatments and AbbVie on its acquisition of a cell therapy developer in a potentially $2.1 billion deal, earning her a spot as one of the 2025 Law360 Life Sciences MVPs.
-
November 26, 2025
Ex-Amarin CEO Loses Suit Over Ouster After Proxy Fight
A New Jersey federal judge on Wednesday tossed a lawsuit against Amarin Pharmaceuticals Inc. from its former CEO over his removal, finding that the allegations did not amount to "good cause" under Swiss law and that no qualifying "change of control" occurred to trigger severance benefits.
-
November 26, 2025
Yale Healthcare Workers Lose COVID Vaccine Mandate Suit
A Connecticut federal judge has again thrown out a complaint brought by several current and former Yale New Haven Health Services Corp. workers, who alleged the healthcare system's COVID-19 vaccine mandate violated their constitutional rights, finding they "have failed to plausibly allege sufficient facts that YNHHS acted under color of state law."
-
November 26, 2025
Abbott Accused Of Miscalculating Workers' Overtime
Abbott Laboratories miscalculated employees' overtime by failing to include periodic award pay in the regular rate of pay when they worked more than 40 hours per week, a former employee said in a proposed collective action in Illinois federal court.
-
November 25, 2025
UnitedHealth Gets OptumRx Antitrust Suit Sent To Arbitration
A group of independent pharmacies must arbitrate their proposed class claims that UnitedHealth-owned OptumRx gatekeeps its network of Medicare prescription patients by imposing unfair fees, a Washington federal judge said Tuesday, concluding the pharmacies haven't shown the arbitration clauses in question are unenforceable.
-
November 25, 2025
Medical AI Co. Accused Of 'Smear Campaign' Against Rivals
Two rivals of medical artificial intelligence platform OpenEvidence have told a Massachusetts federal judge the startup has used the courts in a campaign of "deceit, harassment and defamation" against competitors.
-
November 25, 2025
Investors Say Alexandria Overhyped Leasing, NYC Project
Alexandria Real Estate Equities Inc. investors filed suit in California federal court Tuesday, claiming the real estate investment trust overstated the strength of its leasing business and the projected value of a New York City property, causing the company's stock price to drop once the truth came to light.
-
November 25, 2025
Mich. Pharmacist Gets 46 Months For $4M Fraud Scheme
A former Michigan pharmacist who pled guilty to orchestrating a $4 million Medicare scam was sentenced by a federal judge to 46 months in prison and ordered to pay restitution and forfeit property as part of a plea deal, the U.S. Department of Justice announced.
-
November 25, 2025
Judge Hands SEC Win In Pharma Co.'s CBD Investor Fraud Case
A California federal judge has granted the U.S. Securities and Exchange Commission an early win in its suit against Vivera Pharmaceuticals, its CEO and affiliate Sentar Pharmaceuticals, finding they misled investors about the company's rights to key cannabinoid drug-delivery technology and about how investor money would be spent.
-
November 25, 2025
MVP: Hogan Lovells' Mahvesh A. Qureshi
Mahvesh A. Qureshi, a life sciences partner at Hogan Lovells, advised her client through a deal to acquire Anthos Therapeutics, a biopharmaceutical company that developed a unique stroke treatment, in a transaction that could total $3.1 billion, and led Merck on its up to $1.3 billion purchase of a novel autoimmune drug, earning her a spot as one of the 2025 Law360 Life Sciences MVPs.
-
November 25, 2025
NRDC Tells 9th Circ. EPA Would 'Neuter' Public TSCA Rights
The Natural Resources Defense Council has asked the Ninth Circuit to reject the U.S. Environmental Protection Agency's narrow reading of citizen enforcement rights under the Toxic Substances Control Act, saying it would unfairly restrict challenges to agency inaction.
-
November 24, 2025
Mass. Judge Says States Can Fight Planned Parenthood Cuts
A Massachusetts federal judge on Monday chided a Trump administration lawyer for continuing to argue that a coalition of states lacks standing to seek to block what it says is the effective defunding of Planned Parenthood, even as it only just received a lengthy list of new requirements for Medicaid reimbursement.
-
November 24, 2025
DOJ Demand For Pa. Transgender Patient Records Blocked
A Pennsylvania federal judge partially quashed part of a U.S. Department of Justice subpoena seeking health records for minors receiving gender-affirming care at The Children's Hospital of Philadelphia, ruling that the department lacked the statutory authority "for a rambling exploration" of medical files involving state-sanctioned medical care.
-
November 24, 2025
Full Fed. Circ. Rejects Bayer Petition In Xarelto Patent Case
The full Federal Circuit on Monday declined a petition from German pharmaceutical giant Bayer asking the appeals court to take a look at reviving patent claims related to its blood thinner medication Xarelto.
-
November 24, 2025
Hi-Tech Pharma CEO Beats Most Of Feds' Fraud Case
A Georgia federal jury acquitted Hi-Tech Pharmaceuticals' chief executive on the bulk of the conspiracy, fraud and money laundering charges leveled against him, rejecting allegations that he cheated his customers by drawing up bogus quality certificates.
-
November 24, 2025
Israeli Co. Can't Expand Contract Breach Suit Over $25M Deal
An Israeli smart packaging company can't enlarge a North Carolina Business Court contract breach suit, a judge ruled Monday, saying the amendment would "wholly transform" the case and prejudice defendant Sealed Air Corp.
-
November 24, 2025
Biotechs Go To Del. Chancery Over Cancer Drug Rights
A contract battle has broken out in the Delaware Chancery Court between two biotechs, each accusing the other of materially breaching a decade-old collaboration agreement governing rights to the cancer drug Jemperli.
-
November 24, 2025
FTC Abandons In-House GTCR Merger Case After Court Loss
The Federal Trade Commission formally dropped its administrative case challenging GTCR BC Holdings LLC's acquisition of a medical coatings supplier after an Illinois federal judge refused to put the deal on hold.
-
November 24, 2025
MVP: Cooley's Charity Williams
Charity Williams, a partner in Cooley LLP's life sciences corporate partnering and licensing practice, guided transformative pharmaceutical deals in 2025, including Capstan Therapeutics' $2.1 billion sale to AbbVie, Esobiotec's $1 billion sale to AstraZeneca and Advanced Instruments' $2.2 billion acquisition of Nova Biomedical, earning her a spot as one of the 2025 Law360 Life Sciences MVPs.
-
November 24, 2025
Ophthalmic Co. Hits Ch. 11 With $64M Debt, Eyeing Sale
Clearside Biomedical, a company developing treatments for eye diseases, has filed for Chapter 11 protection in Delaware bankruptcy court with $64 million in debt, saying it will attempt to sell its business during the case.
Expert Analysis
-
Defeating Estoppel-Based Claims In Legal Malpractice Actions
State supreme court cases from recent years have addressed whether positions taken by attorneys in an underlying lawsuit can be used against them in a subsequent legal malpractice action, providing a foundation to defeat ex-clients’ estoppel claims, says Christopher Blazejewski at Sherin and Lodgen.
-
Trade Secret Rulings Reveal The Cost Of Poor Preparation
Two recent federal appellate decisions show that companies must be prepared to prove their trade secrets with specificity, highlighting how an asset management program that identifies key confidential information before litigation arises can provide the clarity and documentation that courts increasingly require, say attorneys at Mintz.
-
Series
The Biz Court Digest: How It Works In Massachusetts
Since its founding in 2000, the Massachusetts Business Litigation Session's expertise, procedural flexibility and litigant-friendly case management practices have contributed to the development of a robust body of commercial jurisprudence, say James Donnelly at Mirick O’Connell, Felicia Ellsworth at WilmerHale and Lisa Wood at Foley Hoag.
-
Why Appellees Should Write Their Answering Brief First
Though counterintuitive, appellees should consider writing their answering briefs before they’ve ever seen their opponent’s opening brief, as this practice confers numerous benefits related to argument structure, time pressures and workflow, says Joshua Sohn at the U.S. Department of Justice.
-
Navigating DEA Quotas: Key To Psychedelics Industry Growth
As new compounds like DOI enter the Schedule I landscape, manufacturers who anticipate U.S. Drug Enforcement Administration quota regulations, and build quota management into their broader strategy, will be best equipped to meet the growing demand, say Kimberly Chew at Husch Blackwell and Jaime Dwight at Promega.
-
Series
Mindfulness Meditation Makes Me A Better Lawyer
Mindful meditation enables me to drop the ego, and in helping me to keep sight of what’s important, permits me to learn from the other side and become a reliable counselor, says Roy Wyman at Bass Berry.
-
Growth, Harmonization In Focus As Hague System Turns 100
One hundred years after its establishment, the Hague System has grown into an important pillar of international design protection, offering a promising path toward even greater harmonization in design law as its geographic reach continues to expand, say attorneys at Sterne Kessler.
-
Lessons From 7th Circ. Decision Affirming $183M FCA Verdict
The Seventh Circuit's decision to uphold a $183 million False Claims Act award against Eli Lilly engages substantively with recurring materiality and scienter questions and provides insights into appellate review of complex trial court judgments, say Ellen London at London & Naor, Li Yu at Bernstein Litowitz and Kimberly Friday at Osborn Maledon.
-
Opinion
Punitive Damages Awards Should Be Limited To 1st Instance
Recent verdicts in different cases against Johnson & Johnson and Monsanto showcase a trend of multiple punitive damages being awarded to different plaintiffs for the same course of conduct by a single defendant, a practice that should be deemed unconstitutional by the U.S. Supreme Court, says Jacob Mihm at Polales Horton.
-
How Calif. High Court Is Rethinking Forum Selection Clauses
Two recent cases before the California Supreme Court show that the state is shifting toward greater enforcement of freely negotiated forum selection clauses between sophisticated parties, so litigators need to revisit old assumptions about the breadth of California's public policy exception, says Josh Patashnik at Perkins Coie.
-
AI Litigation Tools Can Enhance Case Assessment, Strategy
Civil litigators can use artificial intelligence tools to strengthen case assessment and aid in early strategy development, as long as they address the risks and ethical considerations that accompany these uses, say attorneys at Barnes & Thornburg.
-
Attys Beware: Generative AI Can Also Hallucinate Metadata
In addition to the well-known problem of AI-generated hallucinations in legal documents, AI tools can also hallucinate metadata — threatening the integrity of discovery, the reliability of evidence and the ability to definitively identify the provenance of electronic documents, say attorneys at Law & Forensics.
-
Lessons From Fed. Circ. On Expert Testimony In Patent Cases
Several recent decisions from the Federal Circuit are notable for their treatment of expert testimony, with relevance to the three pillars of every patent case — infringement, invalidity and damages — and offer lessons on ensuring that expert testimony is both admissible and sufficient to support the jury's verdict, say attorneys at Honigman.
-
When Atty Ethics Violations Give Rise To Causes Of Action
Though the Model Rules of Professional Conduct make clear that a violation of the rules does not automatically create a cause of action, attorneys should beware of a few scenarios in which they could face lawsuits for ethical lapses, says Brian Faughnan at Faughnan Law.
-
What's New In FDA's Latest Cell And Gene Therapy Guidance
New draft guidance from the U.S. Food and Drug Administration, along with other recent initiatives, come together to promote cell and gene therapy product development by streamlining development and review pathways, say attorneys at Holland & Knight.